RECUVYRA[™] APPROVED BY FDA

Acrux (ASX: ACR) today reported that the US Food and Drug Administration (FDA) has granted approval for commercial use of Recuvyra[™] transdermal solution for dogs. Recuvyra contains the active ingredient fentanyl and is approved for the control of post-operative pain associated with surgical procedures in dogs. A single dose (2.7 ml/kg) applied to the skin of dogs prior to surgery controls pain for at least 4 days. The product was developed using a transdermal drug delivery technology licensed from Acrux by Elanco, a division of Eli Lilly and Company. Elanco's Companion Animal business unit will commercialise Recuvyra.

This represents the first US approval of Acrux's transdermal technology in animal health. Acrux will receive a milestone payment of \$1 million and expects to begin earning royalties on net sales of Recuvyra in the US and Europe during the 2012/13 financial year.

"We are delighted with the news of this first US animal drug approval that utilizes Acrux's transdermal technology. We are looking forward to Recuvyra being launched in the US, as well as additional animal drug approvals utilising our technology," said Richard Treagus, Acrux CEO.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

Acrux is an Australian pharmaceutical company, which developed the innovative delivery technology used in RecuvyraTM. Acrux's technology is based on a fast-drying, small volume liquid, containing penetration enhancers, that when applied topically, deposit drug into the skin for long acting transdermal delivery into the bloodstream. Additional information about Acrux is available at www.Acrux.com.au.

About Elanco

Elanco is a global, innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 2,400 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at www.elanco.com.

